Kutane leukozytoklastische Vaskulitis, Purpura Schönlein-Henoch und kryoglobulinämische Vaskulitis

Zusammenfassung Die leukozytoklastische Vaskulitis, Purpura Schönlein-Henoch und kryoglobulinämische Vaskulitis sind Immunkomplexvaskulitiden, die sich durch Ablagerung verschiedener Immunglobuline in den kleinen Gefäßen unterscheiden und sich meist als palpable Purpura klinisch manifestieren. Die differenzialdiagnostische Abgrenzung und die Unterscheidung der primären von sekundären Formen stellt eine Herausforderung für Rheumatologen dar. Die frühzeitige Detektion extrakutaner Organmanifestationen wie Glomerulonephritis, mesenteriale Vaskulitis oder periphere Neuropathie ist für die Therapieindikation und damit die Prognose der Kleingefäßvaskulitiden essentiell.

[1]  A. Mahr,et al.  Therapeutic plasma exchange in systemic vasculitis: an update on indications and results , 2012, Current opinion in rheumatology.

[2]  Zonghui Hu,et al.  A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. , 2012, Arthritis and rheumatism.

[3]  A. Gabrielli,et al.  A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. , 2012, Arthritis and rheumatism.

[4]  J. Stone,et al.  The cryoglobulinaemias , 2012, The Lancet.

[5]  D. Roccatello,et al.  Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. , 2011, Autoimmunity reviews.

[6]  H. Mahmoodzadeh,et al.  Treatment of Complicated Henoch-Schönlein Purpura with Mycophenolate Mofetil: A Retrospective Case Series Report , 2010, International journal of rheumatology.

[7]  S. Gunturu,et al.  Henoch-Schonlein Purpura—A Case Report and Review of the Literature , 2010, Gastroenterology research and practice.

[8]  H. Raspe,et al.  EULAR recommendations for the management of primary small and medium vessel vasculitis , 2008, Annals of the Rheumatic Diseases.

[9]  F. Dede,et al.  Mycophenolate mofetil treatment of crescentic Henoch–Schönlein nephritis with IgA depositions , 2008, Scandinavian journal of urology and nephrology.

[10]  R. Bratton,et al.  Henoch-Schönlein Purpura: A Review Article , 2007, Southern medical journal.

[11]  J. Piette,et al.  Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. , 2006, Arthritis and rheumatism.

[12]  A. Bryce,et al.  Response to rituximab in patients with type II cryoglobulinemia. , 2006, Clinical lymphoma & myeloma.

[13]  L. Quartuccio,et al.  Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. , 2006, Rheumatology.

[14]  T. Asselah,et al.  Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C , 2006, Hepatology.

[15]  L. Gibson,et al.  Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment , 2006, International journal of dermatology.

[16]  M. Houghton,et al.  Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Fossati-Jimack,et al.  The Role of Complement in Cryoglobulin-Induced Immune Complex Glomerulonephritis1 , 2005, The Journal of Immunology.

[18]  I. Uthman,et al.  Response of deep cutaneous vasculitis to infliximab. , 2005, Journal of the American Academy of Dermatology.

[19]  J. Piette,et al.  PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. , 2005, Arthritis and rheumatism.

[20]  M. Braun,et al.  Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. , 2004, The Journal of rheumatology.

[21]  Claudio Michelassi,et al.  Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. , 2004, Seminars in arthritis and rheumatism.

[22]  G. Kaplanski,et al.  Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. , 2004, Rheumatology.

[23]  R. Fanin,et al.  Efficacy and safety of rituximab in type II mixed cryoglobulinemia. , 2003, Blood.

[24]  B. Zimmerman,et al.  Hepatitis C, cryoglobulinemia, and cirrhosis: A meta‐analysis , 2002, Hepatology.

[25]  R. Ruiz Villaverde,et al.  Annular leucocytoclastic vasculitis: response to dapsone , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  R. Falk,et al.  Cutaneous and Systemic Manifestations of Drug-Induced Vasculitis , 2002, The Annals of pharmacotherapy.

[27]  D. Pyne,et al.  Colchicine for the treatment of recurrent Henoch-Schönlein purpura in an adult. , 2001, Rheumatology.

[28]  Felicia A Tucci,et al.  The cryoglobulins: an overview , 2001, European journal of clinical investigation.

[29]  J. Yagüe,et al.  Cryoglobulinemia: Study of Etiologic Factors and Clinical and Immunologic Features in 443 Patients from a Single Center , 2001, Medicine.

[30]  S. Jessop Cutaneous leucocytoclastic vasculitis: a clinical and aetiological study. , 1995, British journal of rheumatology.

[31]  S. Finegold,et al.  Vasculitides associated with infections, immunization, and antimicrobial drugs. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[33]  S. Bombardieri,et al.  Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. , 1992, The Journal of rheumatology.

[34]  J. Callen,et al.  Cutaneous Leukocytoclastic Vasculitis: Clinical Experience in 44 Patients , 1987, Southern medical journal.

[35]  J. Clauvel,et al.  Biologic and clinical significance of cryoglobulins. A report of 86 cases. , 1974, The American journal of medicine.